Advancing a Safe, long-term therapy for IBS-D

Approach

CinPhloro Pharma, a CinRx portfolio company, is advancing CIN-103 for the treatment of irritable bowel syndrome (IBS) with predominant diarrhea (IBS-D).

IBS impacts ~12% of the U.S. population. Of the 3 subtypes of IBS, IBS-D is the most common form and the leading cause of referral to a gastroenterologist. The disease’s multifactorial and heterogeneous nature makes it difficult to diagnose and treat. It can significantly impact patients’ quality of life physically, emotionally, socially, and economically.

There is a major unmet medical need for patients with IBS-D. The few approved treatments in the U.S. have suboptimal safety and efficacy issues, including:

Black box warnings
Gender-specific prescription criteria
Schedule IV narcotics entailing serious adverse event risks
Inability to be used long-term

CIN-103 is an oral, antispasmodic which has the potential to safely address the heterogenous nature and broad symptoms of IBS-D, including:

Motility
Secretion
Pain
Spams
Inflammation

CIN-103

Candidate

Pre-Clinical Phase 1 Phase 2 Phase 3

CIN-103

- Phase 2

CIN-103 is an oral, pulsatile-release formulation of phloroglucinol, an approved antispasmodic therapy in select countries outside of the U.S., which has been modified for sustained exposure and less frequent dosing.

In clinical trials to date, CIN-103 has demonstrated strong safety and tolerability while achieving the desired pharmacokinetic activity.

CinPhloro is currently enrolling the enviva clinical trial to explore the impact of CIN-103 on the symptoms of IBS-D.

CinPhloro Team

CinPhloro Pharma is a CinRx portfolio company. CinRx deploys a hub-and-spoke approach in advancing its portfolio of multiple biotechnology companies, each rapidly developing high-impact medicines for patients in need.

The CinPhloro team consists of the scientific, technical and clinical development experts from its central team at CinRx Pharma.

For more information about the CinRx model, to meet the team or to view the entire portfolio, visit CinRx.com.